Pharmacotherapy following myocardial infarction - a review of current treatment practices

Bibliography

• REPORT OF THE DIRECTOR GENERAL WHO: World health report. WHO, Geneva, Switzerland (1998).
   Google Scholar
• ANTMANN EM, BRAUNWALD E: Acute myocardial infarction. In: Heart disease(Edition 5). A textbook of cardiovascular medicine. Braunwald E (Ed.) (1997):1185.
   Google Scholar
• RYAN TJ, ANTMAN EM, GIBBONS JR et al.: 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. JACC (1999) 34:890–911.
   Google Scholar
• •One of the dominating international guidelines for treatment of patients with CAD.
   Google Scholar
• PATRONO C, CIABATTONI G, PATRIGNANI P et al.: Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation (1985) 72:177–184.
   Google Scholar
• PATRONO C, COLLER B, DALEN J et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest (1998) 114:470s–488s.
   Google Scholar
• CLARKE RJ, MAYO G, PRICE P, FITZGERALD GA: Suppres-sion of thromboxane A2 but not systemic prostacyklin by controlled-release ASA. N Engl. J Med. (1991) 325:1137–1141.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALIST'S COLLABORATION: Collabora-tive overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81–106.
   PubMedGoogle Scholar
• •A classic overview.
   Google Scholar
• HE J, WHELTON PK, VU B, KLAG MJ: ASA and risk of hemorrhagic stroke: a meta-analysis of randomised controlled trials. JAMA (1998) 280:1930–1935.
   PubMed Web of Science ®Google Scholar
• PITT B, YUSUF S FOR THE SOLVD INVESTIGATORS: Studies of left ventricular dysfunction (SOLVD) subgroup results. j. Am. Coll. Cardiol. (1992) 19:215A.
   Google Scholar
• NGUYEN KN, AURSNES I, KJEKSHUS J: Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am. J. Cardiol. (1997) 79:115–119.
   PubMed Web of Science ®Google Scholar
• OGER RH, BODEBOGER SM KRAMME P et al.: Effect ofcap topril on prostacyclin and nitric acid formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J. Clin. Pharmacol. (1996) 42:721–727.
   Google Scholar
• OOSTERGA M, ANTHONIO RL DE KAM PJ et al.: Effects ofASAon angiotensin-converting enzyme inhibition and Exp. Opin. Pharmacother. (2000) 1(6) left ventricular dilation one year after acute myocar-dial infarction. Am. J Cardiol. (1998) 81:1178–1181.
   Google Scholar
• NAWARSKAS JJ, SPINLER SA: Does ASAinter fere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure? Pharmacotherapy (1998) 18:1041–1052.
   PubMedGoogle Scholar
• •A good review on the pharmacodynamic properties of ASA.
   Google Scholar
• RODERICK PJ, WILKES HC, MEADE TVV: The gastrointes- tinal toxicity of ASA: an overview of randomised controlled trials. Br. J. Clin. PharmacoL (1993) 35:219–226.
   PubMed Web of Science ®Google Scholar
• •A good overview of an important complication of aspirin therapy.
   Google Scholar
• HASS WK, EASTON D, ADAMS HP et al. FOR THE TICLOPIDINE ASA STROKE STUDY GROUP: A random-ised trial comparing ticlopidine hydrochloride with ASA for the prevention of stroke in high-risk patients. N Engl. J. Med. (1989) 321:501–507.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blindedtrial of clopidogrel versus ASA in patients at risk of ischemic events (CAPRIE). Lancet (1996) 348:139–1339.
   PubMedGoogle Scholar
• •A large study that is often referred to.
   Google Scholar
• THE PARIS RESEARCH GROUP: The Per san tin e-ASA Reinfarction Study (PARIS). Circulation (1980) 62:V 85–87.
   Google Scholar
• TJISSEN JGP: Low-dose and high dose acetylsalicylic acid, with and without dipyridamole: a review of clinical trial results. Neurology (1998) 51:S15–16.
   Google Scholar
• ANAND SS, YUSUF S: Oral anticoagulant therapy in patients with coronary artery disease: Ameta-analysis. JAMA (1999) 282:2058–2067.
   PubMed Web of Science ®Google Scholar
• •Good review of current data on oral anticoagulation as secondary prevention.
   Google Scholar
• EZEKOWITZ MD, FIORE L: CHAMP (Combination Hemo therapy and Mortality Prevention): Warfarin plus ASA vs. ASA alone after MI. Presented at the 7211 Annual Session American Heart Association, Atlanta, USA (1999).
   Google Scholar
• RIDKER PM, RIFAI N, PFEFFER MA, SACKS F, BRAUNWALDE: Long-term effects of pravastatin on plasma concen-trations of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 100(3):230–235.
   Google Scholar
• ROSENSON RS, TANGENEY CC: Antiatherothromboticproperties of statins: Implications for cardiovascular event reduction. JAMA (1998) 279:1643.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Circulation (1998) 97:1453–1460.
   PubMedGoogle Scholar
• •Landmark trial on cholesterol lowering in patients with CAD.
   Google Scholar
• SACHS FM, PFEFFER MA, MOVE LA et al. FOR THE CHOLESTEROL AND RECURRENT EVENTS (CARE) TRIAL INVESTIGATORS: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J Med. (1996) 335:1001.
   PubMedGoogle Scholar
• •Landmark trial on cholesterol lowering in patients with CAD.
   Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHEMIC DISEASE (LIPID) STUDY GROUP: Preven-tion of cardiovascular events and death with pravas-tatin in patients with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• •Landmark trial on cholesterol lowering in patients with CAD.
   Google Scholar
• RYAN T, ANDERSON JL, ANTMANN EM et al.: ACC/AHAGuidelines for the management of patients with acute myocardial infarction: Executive summary. Circula-tion (1996) 94:2341–2350.
   PubMed Web of Science ®Google Scholar
• PEDERSEN TR, OLSSON AG, FAEGERMANN 0 et al.: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandina-vian Simvastatin Survival Study (4S). Circulation (1998) 97:1453–1460.
   Google Scholar
• GOULD AL, ROSSOUW ER, SANTANELLOM NC et al.: Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation (1998) 97:946–952.
   PubMed Web of Science ®Google Scholar
• •Good review on statins.
   Google Scholar
• CHEN Z, PETO R, COLLINS R et al.: Serum cholesterolconcentration and coronary heart disease in popula-tion with low cholesterol concentrations. Br. Med. J (1991) 303:276–282.
   PubMed Web of Science ®Google Scholar
• KAPLAN JR, PETTERSON K, MANUCK SB, OLSSON G: Roleof sympatoadrenal medullary activation in the activa-tion and progression of artherosclerosis. Circulation (1991) 84 (Suppl. V):23
   Google Scholar
• WILLICH SN, LINDERER T, WEGESCHNEIDER K et al.:Increased incidence of myocardial infarction in the 'SAM study: absence with prior beta-adr en ergic blockade. Circulation (1989) 80:853.
   PubMed Web of Science ®Google Scholar
• FREEMANTLE N, CLELAND J, YOUNG P, HARRISON J: I3-blockade after myocardial infarction: systematic review and meta regression analysis. Br. Med. J (1999) 318:1730–1737.
   PubMed Web of Science ®Google Scholar
• •A good overview, questioning the use of acute short-term I3-blockade in AMI.
   Google Scholar
• GOTTLIEB SS, MCCARTER RJ, VOGEL RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl. J. Med. (1998) 339:489–497.
   PubMed Web of Science ®Google Scholar
• •A good overview.
   Google Scholar
• RODDA BE: The Timolol myocardial infarction study:an evaluation of selected variables. Circulation (1983) 67:1–101.
   PubMedGoogle Scholar
• EXNER DV, DRIES DL, WACLAWIW MA, SHELTON B, DOMANSKI MJ: Beta-adrenergic blocking agent use and mortality in patients with asymptomatic left ventricular systolic dysfunction: a post-hoc analysis of the studies of left ventricular dysfunction. j Am. Coll Cardiol. (1999) 33:916-923. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• VANTRIMPONT P, ROULEAU JL, WUN CC et al. FOR THE SAVE INVESTIGATORS: Additive beneficial effects of beta blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlarge-ment (SAVE) study. J. Am. Coll. Cardiol. (1997) 29:229.
   PubMed Web of Science ®Google Scholar
• CIBIS-II INVESTIGATORS and COMMITTEES: The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a random-ised trial. Lancet (1999) 353:9–13.
   PubMedGoogle Scholar
• •The first large trial to show a mortality benefit of I31-selective I3-blockers in heart failure.
   Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CX/XL Random-ised Intervention Trial in Congestive heart failure (MERIT-I IF) . Lancet (1999) 353:2001–2006.
   PubMed Web of Science ®Google Scholar
• COLUCCI WS, PACKER M, BRISTOW MR et al. for the US CARVEDILOL HEART FAILURE STUDY GROUP: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation (1996) 94:2800–2806.
   PubMed Web of Science ®Google Scholar
• •The first large trial to show a mortality benefit from 13-blockers in patients with heart failure.
   Google Scholar
• CLELAND JGF, MCGOWAN J, CLARK A, FREEMANTLE N: The evidence for I3-blockers in heart failure. Br. Med. J. (1999) 318:824–825.
   PubMedGoogle Scholar
• LUI YH, YANG XP, SHAROV VG et al.: Effects ofangiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin. Invest. (1997) 99:1926–1935.
   Google Scholar
• GRUPPO ITALIANO PER 10 STUDIO DELLA SOPRAV-VIVENZA NELL'INFARTO MIOCARDIO. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet (1994) 343:1115–1122.
   Google Scholar
• ISIS-4 COLLABORATIVE GROUP: ISIS-4: A randomisedfactorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet (1995) 345:669–685.
   PubMed Web of Science ®Google Scholar
• •One of the large important postinfarction treatment trials.
   Google Scholar
• ACE INHIBITOR MYOCARDIAL INFARCTION GROUP: Indications for ACEinhibitors in the early treatment of acute myocardial infarction. Circulation (1998) 97:2192–2194.
   PubMedGoogle Scholar
• •A good overview.
   Google Scholar
• SWEDBERG K, HELD P, KJEKSHUS J et al. CONSENSUS II STUDY GROUP: Effects of early administration of enalapril on mortality in patients with acute myocar-dial infarction. N Engl. J. Med. (1992) 327:678–684.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, BRAUNVALD E, MOYE LA et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarc-tion: results of the Survival And Ventricular Enlarge-ment Trial (SAVE). N Engl. J. Med. (1992) 327:669–677.
   PubMed Web of Science ®Google Scholar
• ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS: Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet (1993) 342:821–828.
   PubMed Web of Science ®Google Scholar
• KOBER L, TORP-PEDERSEN C, CARLSEN JE et al.: A clinicaltrial of the angiotensin-converting -enzyme inhibitor in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (1995) 333:1670–1676.
   PubMed Web of Science ®Google Scholar
• YSUF S, SLEIGHT P, POGUE J, et al. for the HEARTOUTCOMES PREVENTION EVALUATION STUDY INVESTI-GATORS: Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl. J Med. (2000) 342:145–153.
   PubMedGoogle Scholar
• •Important study, extending the use of ACE inhibitors.
   Google Scholar
• TSEVAT J, DUKE D, GOLDMAN L et al.: Cost-effectiveness of captopril therapy after myocardial infarction./ Am. Coll. Cardiol. (1995) 26(4):914–919.
   Google Scholar
• STRUTHES AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur. Heart J. (1995) 16:103–106.
   Google Scholar
• •Gives the rationale for both direct angiotensin receptor blockade and aldosterone antagonism in patients receiving ACE inhibitors.
   Google Scholar
• VAN KATS J, DANSER A, VAN MEEGEN J, SASSEN L, VERDOUW P, SCHALEKAMP M: Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation (1998) 98:73–81.
   PubMedGoogle Scholar
• •Important demonstration and quantification of tissue production of angiotensin II.
   Google Scholar
• MILAVETZ JJ, RAYA TE, JOHNSON CS et al.: Survival aftermyocardial infarction in rats: captopril versus losartan.J. Am. Coll. Cardiol. (1996) 27:714–719.
   PubMed Web of Science ®Google Scholar
• PITT B, SEGAL R, MARTINEZ FA et al., ON BEHALF OF THEELITE STUDY INVESTIGATORS: Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet (1997) 349:747–752.
   PubMed Web of Science ®Google Scholar
• PITT B, POOLE-WILSON PA, SEGAL R et al ON BEHALF OFTHE ELITE II STUDY INVESTIGATORS: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582–1587.
   PubMed Web of Science ®Google Scholar
• •The first large mortality trial on an angiotensin II receptor antagonist.
   Google Scholar
• DICKSTEIN K, KJEKSHUS J FOR THE OPTIMAAL STUDYGROUP: Comparison of effects of losartan and captopril on mortality in patients after acute myocar-dial infarction: the OPTIMAAL trial design. Am. J Cardiol (1999) 83:477–481.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA: Enhancing cardiac protection after M1:Rationale for newer clinical trials of angiotesin recpetor blockers. Am. Heart J. (2000) 139 (Suppl.):S23–S28.
   Google Scholar
• HULLEY S, GRADY D, BUSH T et al.: Heart andestrogen /progesterin replacement study/HERS. JAMA (1998) 280:605–613.
   PubMed Web of Science ®Google Scholar
• •HERS was the first study that investigated the effect of HRT in women with CVD in a prospective and randomised Exp. Opin. Pharmacother. (2000) 1(6) manner. This study caused a shift in paradigm by showing a possibly negative effect of HRT.
   Google Scholar
• GOLDBOURT U, BECHAR S, REICHER-REISS H et al.:Early administration of nifedipine in suspected acute myocardial infarction: the Secondary Prevention Reinfarction Israeli Mfedipine Trial 2 Study. Arch. Intern. Med. (1993) 153:345.
   PubMed Web of Science ®Google Scholar
• REPORT OF THE HOLLAND INTERUNIVERSITY NIFEDIPINE /METOPROLOL TRIAL (HINT) RESEARCH GROUP: Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br. Heart J. (1986) 56:400.
   PubMedGoogle Scholar
• BODEN WE, KRONE RJ, KLEIGER RE et al: Diltiazem reduces long term cardiac event rate after non-Q wave infarction. Circulation (1988) 78 (Suppl.
   Google Scholar
• THE DANISH STUDY GROUP ON VERAPAMIL IN MYOCARDIAL INFARCTION: Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am. J. Cardiol. (1990) 66:779.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of Spironolactone on morbidity and mortality in patients with Severe heart failure. N. Engl. J. Med. (1999) 341:709–716.
   PubMed Web of Science ®Google Scholar
• •A landmark study on aldosterone inhibition. Stein Orn & Kenneth Dicksteint
   Google Scholar